MedTrace Logo

Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

NCT06467617 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-12-16

No results posted yet for this study

Summary

Current studies confirmed that the immune perioperative treatment with combination chemotherapy curative effect and safety of resectable NSCLC, but its short-term curative effect and long-term survival benefit remains to be further improved to explore the new way of immune combination therapy.

Experimental study showed that the inhibition of PCSK9 could significantly increase in tumor cells of the immune response in mice, inhibit the PCSK9 enhanced anti-tumor immune response of mice can be further coordinate with immune checkpoint therapy, forming a lasting anti-tumor immune effect.

There are no reports on the peri-operative treatment of immune combined with chemotherapy and PCSK-9 inhibitors in patients with resectable NSCLC.

Based on the above, the aim of this study is to explore the efficacy and safety of Adebrelimab combined with recaticimab and chemotherapy in the perioperative treatment of patients with resectable NSCLC.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab

Adebrelimab (1200 mg,IV, D1, Q3W) + albumin-bound paclitaxel (260 mg/m2, IV, divided by D1,8,Q3W) + carboplatin (AUC 5mg/mL/min, IV, D1,Q3W) + recaticimab (150 mg, SC, D1,Q3W) 21-day cycle

Sponsors & Collaborators

  • Beijing Chest Hospital, Capital Medical University

    lead OTHER

Principal Investigators

  • Jinghui Wang · Director of Research Laboratory, Beijing Chest Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-14
Primary Completion
2026-08-01
Completion
2027-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06467617 on ClinicalTrials.gov